Thermo Fisher Scientific Inc.
NYSE:TMOMedical - Diagnostics & Research
+$4.45 today
- Market cap
- $256.67B
- Beta
- 0.87
- P/E (TTM)
- 25.3
- EPS (TTM)
- $18.44
- Dividend yield
- 0.39%
Volume 1.99M
Average 2.23M
TMO Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Thermo Fisher Scientific Inc.NYSE: TMO
Revenue · Q3 FY2026 · quarter ended Sep 2026
Revenue grows in line with its trailing trend
Q3 FY2026 revenue of $12.14B rose 9.1% year over year, ahead of the +8.3% change in trailing-twelve-month revenue. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 20 analysts of $48B (+7.7%) for the fiscal year ending Dec 2026, a step up from the +3.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $12.14B+1.2% QoQ
- Last fiscal yearDec 2025
- $44.56B+3.9% YoY
- LTMSep 2026
- $47.35B+8.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +9.1% | +5.1% | -4.0 pp |
| 1 year | +3.9% | +7.7% | +3.8 pp |
| 3-year CAGR | -0.3% | +6.5% | +6.7 pp |
| 5-year CAGR | +5.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 44.56B USD
- Year-over-year change
- +3.9%
- 4-year CAGR
- +3.2%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 44.56B | +3.9% |
| FY2024 | 2024-12-31 | 42.88B | +0.1% |
| FY2023 | 2023-12-31 | 42.86B | -4.6% |
| FY2022 | 2022-12-31 | 44.92B | +14.5% |
| FY2021 | 2021-12-31 | 39.21B | — |
Revenue vs competitors
How TMO compares with its peers on the latest reported figures
- TMO's LTM Sep 2026 revenue of $47.35B is the highest of the 10 companies compared; the peer median is $3.5B.
- Its year-over-year change of +8.3% is the 3rd highest of 10, against a peer median of +4.1%.
- Over three fiscal years its annual growth of -0.3% compares with a peer median of +0.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $47.35B | +8.3% | -0.3% | |
| LTM Sep 2026 | $25.61B | +5.5% | -2.7% | |
| LTM Jul 2026 | $7.37B | +8.6% | +0.5% | |
| LTM Jul 2026 | $4.64B | +52.5% | +2.1% | |
| LTM Jun 2026 | $4.13B | +6.9% | +0.9% | |
| LTM Jun 2026 | $3.5B | +1.6% | +10.7% | |
| LTM Jul 2026 | $2.91B | +4.1% | -4.8% | |
| LTM Jun 2026 | $2.59B | +1.4% | -2.7% | |
| LTM Jun 2026 | $2.1B | +3.0% | -0.8% | |
| LTM Sep 2026 | $1.23B | +0.9% | +2.2% | |
| Peer median (excluding TMO) | $3.5B | +4.1% | +0.5% | |
Competitors are the stored peer set for TMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 39.21B | 44.92B | 42.86B | 42.88B | 44.56B |
| Cost of Revenue | 19.58B | 25.9B | 25.66B | 25.15B | 26.32B |
| Gross Profit | 19.63B | 19.01B | 17.19B | 17.73B | 18.24B |
| Gross Margin | 50.1% | 42.3% | 40.1% | 41.3% | 40.9% |
| Research & Development | 1.41B | 1.47B | 1.34B | 1.39B | 1.4B |
| Selling, General & Admin | 7.91B | 9.02B | 8.41B | 8.68B | 8.73B |
| Operating Expenses | 9.32B | 10.49B | 9.75B | 10.07B | 10.13B |
| Depreciation & Amortization | 2.59B | 3.38B | 3.41B | 3.11B | 2.78B |
| EBITDA | 11.97B | 11.94B | 11.2B | 11.8B | 11.47B |
| EBITDA Margin | 30.5% | 26.6% | 26.1% | 27.5% | 25.7% |
| Operating Income | 10.32B | 8.53B | 7.45B | 7.66B | 8.11B |
| Operating Margin | 26.3% | 19.0% | 17.4% | 17.9% | 18.2% |
| Interest Income | 43M | 272M | 879M | 1.08B | 993M |
| Interest Expense | 536M | 726M | 1.49B | 1.65B | 1.42B |
| Other Income / Expenses | (1.48B) | (862M) | (1.21B) | (667M) | (842M) |
| Income Before Tax | 8.84B | 7.66B | 6.24B | 7B | 7.27B |
| Pre-Tax Margin | 22.5% | 17.1% | 14.6% | 16.3% | 16.3% |
| Income Tax Expense | 1.11B | 703M | 284M | 657M | 547M |
| Net Income | 7.73B | 6.95B | 6B | 6.34B | 6.74B |
| Net Margin | 19.7% | 15.5% | 14.0% | 14.8% | 15.1% |
| EPS (Basic) | 19.61 | 17.73 | 15.53 | 16.58 | 17.77 |
| EPS (Diluted) | 19.46 | 17.64 | 15.45 | 16.53 | 17.74 |
| Weighted Avg Shares | 394M | 392M | 386M | 382M | 376M |
| Weighted Avg Shares (Diluted) | 397M | 394M | 388M | 383M | 377M |
Thermo Fisher Scientific Inc.
NYSE:TMO
Intrinsic Alpha fair value
Locked
Current Price
$692.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.